

Keyword Index

- [³H]thymidine incorporation 625
15d-PG₂ 1303
16q 1763
17 β -oestradiol 136
1q 1763
2-(4-aminophenyl) benzothiazole 1348
5-aminolaevulinic acid 989
5-aza-2'-deoxycytidine 979
5-fluoropyrimidine 1670
5-fluorouracil 1028, 1162, 1677, 1871
5-FU 222
9-aminocamptothecin 1634
 α -foetoprotein 728
 α -particle emitter ²¹³Bi 1197
 α_v -integrins 788
accelerated hyperfractionation 517
accelerated radiotherapy 1848
actin cytoskeleton 1188
actinomycin D 1174
active specific immunotherapy (ASI) 1230
acute lymphoblastic leukaemia 1727
acute myeloid leukaemia 60, 1061
adaptation 1540
adenocarcinoma 1238
adenocarcinoma of unknown primary 1884
adenocortical tumours 1561
adenovirus 436
adhesion 1169
adjuvant androgen deprivation 1843
adjuvant chemotherapy 1578
adjuvant treatment 1534
adolescent weight 84
adrenal cortex 1561
adult body size 84
advanced epithelial ovarian cancer 1385
advanced oesophageal cancer 669
adverse drug reaction 12
aetiology 60, 350, 1061, 1070, 1745
AF15Q14 1757
affected and unaffected women 43
agarose 947
age 1061, 1373
Akt 540, 1586
ALA 837
ALA derivatives 837
alcohol 346
ALL 356
alternating therapy 692
alternative splicing 737
AMF 1914
aminolaevulinic acid 1343
aminolevulinic acid 837
anaemia 1243
anaplastic astrocytoma 501
anaplastic thyroid carcinoma 1848
androgen receptor 879
androgens 879
angiogenesis 123, 244, 301, 389, 417, 490, 558, 744, 761, 779, 788, 796, 864, 905, 993, 1391, 1465, 1566, 1597, 1622, 1803, 1813
angiogenic factors 768, 1276
angiopoietin 645
anthracycline-resistant 1367
anthracyclines 226, 811
anthranoids 1494
anti-angiogenesis 803, 1813
antiangiogenesis 788
anticancer drugs 1316
antidepressive agents 92
antioxidant activity 1645
antisense 1328, 1957
antivascular 1937
Apaf-1 587
Apaf-3 596
Aplidine 1510
apoptosis 130, 143, 443, 463, 587, 636, 737, 744, 828, 893, 963, 971, 1012, 1104, 1188, 1303, 1316, 1479, 1494, 1510, 1776, 1937, 1951, 1957, 1963
aspirin 1501
ATP 619
autoantibodies 1824
auto-immune disease 1078
autologous melanoma vaccine 1534
autologous tumour cell vaccines 1230
avidin–biotin 207
axillary node status 870
 β -catenin 1124
 β -glucuronidase 811
 β 3-adenoceptor 424
 β -carotene 698
B cells 1336
B lymphocytes 1776
B16 F10 melanoma 803
basic fibroblast growth factor 31, 123, 1770
Bax 1117
BAX 744
Bayesian 843
Bcl-1 143, 971, 1117, 1501, 1561
BCL-2 886
bcl-2 1899
Bcl-2 phosphorylation 463
BCR–ABL 1472
benign thyroid disease 1745
bereavement 1540
beta 2-microglobulin 1943
Betaig-h3 1923
bile acids 1741
birth length 89
birth weight 84, 89, 728
bisphosphonates 1479
bladder cancer 1283, 1732
bladder carcinoma 326
bladder neoplasms 1276
blomycin 1658
body surface area 1297
bombesin receptor 1322
bone marrow micrometastasis 1047
bone marrow stroma 1136
bone metastases 322, 1715
brain cancer 1732
brain tumour 14, 1414
brain tumours 1070
brain-specific angiogenesis inhibitor 1 490
BRCA1 mutation 218
BRCA2 mutation 218
BRCA3 76
breast 250, 905
breast and ovarian cancer genetics 43
breast cancer 84, 89, 218, 222, 362, 540, 580, 723, 728, 750, 870, 1041, 1367, 1373, 1436, 1440, 1457, 1479, 1705, 1786
breast cancer predisposition 718
breast cancer prognosis 1790
breast cancer risk 718
breast carcinoma 546
breast feeding 1064
breast neoplasm 1034
breast neoplasms 92
breast tumour 136
butyrate transport 1262
CA 15-3 1217
CA19-9 1551
cachexia 372, 424, 1628
Caco2 1645
calcium signalling 636
caloric restriction 1615
cancer 51, 636, 698, 1243, 1336, 1634, 1854, 1963
cancer cachexia 612, 1012
cancer chemotherapy 811, 983
cancer in spouses 1737
cancer metastasis 161
cancer network 313
cancer testis antigens 979
cancer/testis (CT) 1757
cancer therapy 130, 449, 652
capecitabine 1367, 1670
carbonic acid 1276
carboplatin 1379, 1385
carcinogenesis 1124, 1494
carcinoma 893, 1444
carcinoma of breast 396
carcinoma of unknown primary site 1238
cardiolipin peroxidation 1951
cardiotoxicity 226, 534, 1697
cardiovascular disease 698
carnitine 1854
case–control 350, 1721, 1751
case–control studies 92, 1425, 1085
case–control study 346, 712, 1436, 1745
case-mix 331
caspase 443
caspase activity 971
caspase-9 587
caspase-independent 828
caspases 143, 893, 1479
caveolin-1 912
C-cell hyperplasia 1929
CCND1 expression 580
cdc25A 1909
cdc25B 1909
CD1a 546
CD20 1336
CD83 546
CEA 1217
cell adhesion 161
cell cycle 443, 1501, 1510, 1645
cell cycle markers 402
cell hypoxia 1276
cell line 98
cell surface molecules 1776
cell proliferating activity 1893
cellular proliferation 1776
cellular telephones 348
census 350
central nervous system tumours 1727
central primitive neuro-ectodermal tumours 1117
c-erbB-2 568
cervical cancer 263, 1188
cervical carcinoma 705
cervical disease 269
CGH 929
change detection analysis 870
chemoembolization 196
chemo-immunotherapy 1230
chemoprevention 218, 774
chemoradiotherapy 552, 1551
chemotaxis 993
chemotherapy 19, 26, 179, 213, 336, 485, 501, 669, 744, 1546, 1555, 1670, 1677, 1684, 1854, 1905
chemotherapy duration 1705
childhood 356
childhood/adolescence 362
childhood cancer 63, 350, 1078, 1727

- childhood cancer risks 1721
 childhood leukaemia 732,
 1064, 1411, 1419
 children 1070
 CHK2 756
 cholecystectomy 1081
 chondrosarcoma 1303
 choroid plexus 1592
 chromatin 1817
 chromosomal abnormalities
 60, 1061
 chromosome 12 1763
 chronic myelogenous
 leukaemia 1487
 cimetidine 161, 630, 1257
 CIN 376
 ciprofloxacin 443
 circadian 999
 circulating tumour cells 110
 cisplatin 19, 196, 213, 326,
 342, 485, 530, 669, 819
 cisplatin 1858
c-kit (CD117) 1333
 clodronate 1235
 cluster analysis 1093
 CMRF-44 546
 CMRF-56 546
 coagulation 389
 cohort studies 70, 1430
 cohort study 723
 colon 1494
 colon cancer 1230, 1262, 1501
 colon carcinoma 409, 1871
 Colon 38 tumour 1937
 colonic cells 1316
 colony stimulating factors 1316
 colorectal 102
 colorectal cancer 161, 203, 331,
 443, 568, 574, 417, 1124,
 1257, 1401, 1670, 1684,
 1691, 1741, 1876, 1884
 combination 534
 combination therapy 819
 combined treatment modality
 1848
 combretastatin A-4 1604
 communication 51
 communication skills 1057
 comparative genomic
 hybridisation 924
 computer 51
 computer-assisted cytology 382
 conformal radiotherapy 1843
Congou tea 346
 cost and cost analyses 226
 cost effectiveness analysis
 1677
 costs 1684
 CPT-11 983
 cryosurgery 1658
 crystallization 196
 CTLs 151
 CXCL12 1250
 CXCR4 1250
 cyclin A 402
 cyclin B1 promoter 477
 cyclin D1 402
 cyclooxygenase-2 1150
 cyclophosphamide 130, 534,
 1705
 CYP1A1 1348
 CYP1B1 774
 CYP26A1 605
 cytarabine 1472
 cytochrome *c* 893, 1479, 1951
 cytochrome P450 630, 774
 cytogenetics 60, 1061
 cytokeratin-positive cells 1047
 cytokeratin staining 1884
 cytokine 449
 cytokines 1310

 D40 1757
 daycare 1064, 1419
 DC activation 546
 declopramide 971
 delayed exposure 1419
 delayed type hypersensitivity
 (DTH) 1534
 dendritic cell 1257, 1529
 dendritic cells 151, 546
 deoxycholic acid 1741
 deprivation 331
 DFF 596
 diabetes 1078
 diagnosis 1444
 diagnostic delay 1034
 diet 712
 dietary factors 1745
 differentiation 117, 1006
 diffusion 1639
 disease-progression 31
 divalent-Fab' maleimide 1401
 DMXAA 1937
 DNA breaks 130
 DNA double-stranded breaks
 1143
 DNA fragmentation 1012
 DNA methylation 282, 574,
 1817, 1888
 DNA mismatch repair 1130
 DNA ploidy 1110
 DNA repair 130, 1797
 DNA sequencing 1117
 DNA-PK 1143
 do not attempt resuscitation
 orders 1057
 docetaxel 326, 692, 1385
 dose calculation 1297
 dose response 1235
 dose-dense chemotherapy 1555
 dose-finding study 1385
 doxorubicin 1093, 1322, 1697,
 1848
 DPD 222, 1028
 DPYD gene 1028
 drug delivery 652
 drug interactions 1162
 drug resistance 1130, 1652
 DS-sarcoma 1355
 ductal carcinoma *in situ* 905

 E-cadherin 98
 E6 oncogene 269
 early infections 1064
 early life factors 356

 EBERs 702
 EGF receptor 456
 EGFR 1518
 EGFR-TKI 1157
 endocrine treatment 540
 endocytic vesicles 652
 endogenous superantigen 828
 endometrial cancer 1837
 endometrial neoplasms 1430
 endometrium 761
 endothelial 1937
 endothelial-cell 1597
 endothelial cells 645, 779, 993,
 1813
 endothelial phenotype 905
 endothelial proliferation index
 761
 energy metabolism 424, 1615
 energy restriction 362
 ependymoma 929
 epidemiology 92, 348, 698,
 1411, 1751
 epidermal growth factor
 receptor 1328
 epirubicin 1385
 epithelial ovarian cancer 879
 Epstein–Barr virus 702
 ER β 250
ErbB-2 540
ErbB2 1104
 erythropoietin 1858
 ethnicity 367
 etoposide 12, 19, 485, 1472
 etoposide phosphate 12
 evidence-based medicine 313
 Ewing tumours 1763
 exercise 70
 expression 917
 expression cloning 1943
 extracellular matrix 1639

 Fab 954
 familial breast cancer 233
 familial cancer 718, 1737
 family 1540
 Fas 963
 fatigue 1854
 FEC 692
 female serum 203
 FHIT 376
 fibrinogen 389
 fibroblast growth factor 8 1097
 FIGO stages 274
 first line therapy 1677
 FISH 1449
 flavonoids 1645
 Fluoro-desoxi-glucose uptake
 1391
 fluoropyrimidine 1367
 fluorouracil 819
 fragments 1401
 free PSA 203
 frozen tissue 1658
 functional genomics 1250

 G0/G1 arrest 1150
 gain Iq 929
 galanin 117

 gallstones 1081
 gamma dose rate 1727
 gastric adenocarcinoma 702
 gastric cancer 564, 674, 1047,
 1578, 1858, 1864
 gastric carcinoma 1223
 gelatinase activity assay 1876
 gelatin zymography 1876
 gemcitabine 190, 342, 843,
 1551, 1701
 gene amplification 1449
 gene expression 274, 1093,
 1262
 gene expression patterns 1283
 gene overexpression 899
 gene therapy 436
 genetic epidemiology 1737
 genetic risk assessment 233
 germ cell cancer 506
 germ-cell tumours 1555
 Glasgow osteosarcoma 999
 Gleevec 1487
 glioblastoma 1328
 glioblastoma multiforme 501
 glioma 14, 207, 587, 619,
 1586, 1615
 glioma c6 1006
 Glivec 1487
 glucose transport 1262
 glucuronide 811, 1634
 glutathione 1180
 glycolysis 1615
 glypican 3 1920
 GM-CSF 292
 Gompertz equation 947
 grade 185
 graft-vs-leukaemia 828
 growth control 1023

 H₂ receptor antagonist 1257
 haem metabolism 630
 haemoglobin 1243
 hCG β 185
 hDFM 1401
 head and neck cancer 512, 517
 head and neck cancer cell lines
 819
 head and neck neoplasms 196
 health behaviour 1034
 heparanase 1270
 heparin 1803
 hepatic artery infusion 436
 hepatobiliary cancer 1732
 hepatocarcinogenesis 630
 hepatocellular carcinoma 98,
 110, 524
 HER-2/neu 1449
 heredity 1737
 heregulin β 1540
 hexyl–ALA 837
 HIF-1 1914
 high-dose chemotherapy 506
 high-grade glioma 501, 1899
 high-risk families 76
 histological grade 396
 histopathological
 differentiation 1893
 histone acetylation 1817

- historical cohort 356
 HLA class I 1336
 HMG Co-A reductase inhibitors 1436
hMLH1 574
 hMLH1 564
 Hodgkin and Reed Sternberg cells 1333
 hormone refractory 1715
 hospital 331
 HPV 263, 376
 human 1444
 human breast cancer 402, 1097
 human bronchial epithelial cells 1923
 human fusion protein 811
 human granulocyte colony-stimulating factor 1858
 human kallikrein 6 1790
 human kallikrein 10 1790
 human kallikrein 13 1457
 human papillomavirus (HPV) 382, 705, 924
 human papillomavirus 16 269
 human squamous cervical cancer 274
 humanised antibody 1401
 hyaluronan 947
 hypercalcaemia 680, 1235
 hyperlipidaemia 1436
 hypermethylation 564
 hypersensitivity 12
 hyperthermia 1597
 hypoxia 136, 301, 1355, 1914
 hypoxia markers 1831
- IAPs 737
 ICAD 596
 IL-1 β 1396
 IL-4 receptor 285
 IL-6 1396
 IL-8 301
 image processing 1831
 imaging 1401
 imatinib 1487
 immune activation 1691
 immune infiltrate 1444
 immune monitoring 168
 immunofluorescence 285
 immunohistochemistry 222, 568, 912, 1449, 1770, 1831, 1888, 1909
 immunotherapy 336, 979, 1336
 incidence rate 1061
 individual 51
 induction chemotherapy 530
 infection 732, 1070, 1414
 infiltrating lymphocytes 1465
 inflammation 1615
 infusional 5-FU 213
 inhibition 768
 inhibitor 605
 inhibitor of apoptosis 886
 insulin-like growth factor-binding protein-3 (IGFBP-3) 1963
 integrin receptor 1923
 interferon α 179
- interleukin-2 179
 interleukin-6 389
 intermediate ploidy 929
 internal ribosome entry sites (IRES) 1023
 International Germ-Cell Cancer Consensus Group 1555
 International Neuroblastoma Pathology Classification (INPC) 1110
 International Neuroblastoma Staging System (INSS) 1110
 interventional radiology 524
 intradermal 336
 intramuscular administration 63
 intra-pleural 336
 intratumour injection 429
 intravenous infusions 1670
 invasive carcinoma 905
 Ip deletion 596, 1110
 Iressa 456, 1157
 irinotecan 530, 999, 1677
 irradiation 1487
 isolated limb perfusion 1174
 isolated liver perfusion 436
in vitro cell model 1283
- Jak 449
 JNK 1188
- kallikreins 1457
 Ki-67 1561
 kidney 768
 kidney cancer 1250
 kidney neoplasms 1425
 Kuwait 1745
- lactation 1097
 laminin 1169
 landfills 1732
 larynx 239, 1751
 late rectal toxicity 1843
 leukaemia 63, 143, 292, 1414, 1721, 1732
 Li Fraumeni 1592
 light dose fractionation 989
 lipid mobilizing factor 424, 612
 liposomal doxorubicin 1379
 liposomes 837
 liquid-based cytology 382
 liver cancer 625
 liver cirrhosis 1290
 liver metastases of colorectal cancer 524
 liver metastasis 436
 locally advanced NSCLC 190
 locoregional chemotherapy 524
 long control region 269
 losoxantrone 534
 loss 22 929
 loss of heterozygosity 574
 LoVo xenograft 1157
 LMR-12 1943
 LRP 954
 Lsm1 940
 lung 1751
- lung adenocarcinoma 1884
 lung cancer 36, 244, 1449, 1757, 1893
 lymphoma 1414
- MAGE transcript 110
 male genital tract 705
 malignant pleural mesothelioma 342
 malignant progression 1355
 MAPK 1518
 marimastat 1864
 mathematical model 14
 matrix metalloproteinase 1136, 1876
 matrix metalloproteinase inhibitors 1864
 MCF 1238
 MDM2 1290
 medical audit 313
 medical practice 313
 medulloblastoma 285
 melanoma 102, 179, 301, 1085, 1529, 1957
 menopause 1430
 mesothelioma 979
 metabolism 605
 metastasis 123, 301, 389, 409, 744, 803, 1136, 1169, 1604, 1803, 1914
 metastatic breast cancer 692, 1905
 metastatic colorectal cancer 1677
 metastatic gastric cancer 213
 methotrexate and fluorouracil (CMF) 1705
 methylating agents 1797
 methylation 979
 metoclopramide 971
 MGMT 1797
 MHC class I 1943
 microarray 1093
 microcirculation 1604
 microenvironment 1615
 micrometastases 396
 microvessel count 1770
 microvessel density 1391, 1566, 1905
 migration 1169
 minimal-disease 102
 mitochondria 619, 1951
 Mitomycin C 470
 MMACI 257
 MMPs 993
 MO7e 292
 molecular cytogenetics 1763
 molecular diagnosis marker 274
 monoclonal 250
 monocytes 1310
 motility 1914
 MRS 963
 m-THPC 1130
 multidrug resistance 292, 954, 1494, 1943
 multidrug resistance-associated protein 1 1578
- multiple cancer 564
 multiple comparisons 1093
 multiple gated acquisition scan 226
 multiple myeloma 796
 multivariate analysis 1217, 1899
 muscle 372
 mutation 1028, 1920
 MVD 796
 MVP 954
 Mxi1 477
 MYCN amplification 1110
 myo-inositol 1180
 myotubes 1628
- N-(4-hydroxyphenyl)retinamide 1951
 NASBA 102
 nasopharyngeal carcinoma 843
 natural compound 1510
 NDGA 1188
 neoadjuvant androgen deprivation 686
 neoadjuvant chemotherapy 190, 750, 1041
 neoplasias 917
 neoplasm 768, 924
 neoplasm staging 1034
 nested polymerase chain reaction 110
 neuroblastic tumour 117
 neuroblastoma 117, 485, 596, 1110
 neuroectodermal 596
 nipple aspirate fluid 1440
 nitric oxide 1310
 nitric oxide synthase 136
 nitric oxide synthase II 1310
 nitrosoureas 1797
 NMR 1180
 non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) 1803
 non-Hodgkin's lymphoma 1414, 1727, 1770
 non-seminomatous germ-cell tumours 1555
 non-small cell lung cancer 530, 1701
 normal 1963
 NS-398 1150, 1501
 NSCLC 858
 NUCB2 1824
 nutrient deprivation 1343
- O*⁶-methylguanine-DNA methyltransferase 1888
 occult metastases 396
 occupational physical activity 70
 ocular melanoma 348
 oesophageal cancer 346, 552
 oesophageal carcinoma 1223
 oesophagectomy 851
 oesophagus 1751
 oestradiol 728
 oestrogen receptor 250, 282

- oestrogens 367, 1430
 omega-3 fatty acids 983
 oncogene overexpression 1449
 ONYX-015 5
 OPS 1622
 oral 1670, 1751
 oral cavity 239
 oral contraceptives 1085
 organometallic arene complexes 1652
 osteosarcoma 864
 ovarian cancer 19, 282, 456, 712, 1180, 1379
 ovarian surface epithelium 879
 ovarian xenografts 1652
 ovulation 367
 oxaliplatin 999, 1162, 1871
 oxidative stress 630, 779
- PI4ARF* 1290
 p21 1150
 p21^{WAF1/CIP1} 625
 p53 5, 490, 587, 744, 750, 756, 886, 1104, 1518, 1561, 1592
 p53 proteins 1117
 p73 263
 p9Ka 409
 paclitaxel 669, 1367, 1379, 1858
 palliative chemotherapy 1858
 pancreas 257, 893
 pancreatic cancer 680, 1081, 1188, 1551
 pancreatic ductal adenocarcinoma 1270
 pancreatic neoplasms 886
 Pap smear 382
 parathyroid hormone-related peptide 322
 parity 1425
 participation 350
 paternal occupational contacts 732
 pathological response 1041
 pathology 674
 PC3 cell line 1197
 PCR-RFLP 568
 p-dimethylaminoazobenzene 630
 PDT 837
 peptide 1169, 1529
 perforin 828
 pericyte 645
 periodate-treated 1803
 peripheral blood 1715
 peripheral blood stem cell support 1715
 PET 506, 1391
 P-glycoprotein 1578
 phage display 954
 pharmacogenetics 1028
 pharynx 239
 phase I study 1701
 phase I/II trial 1401
 Phase II clinical trial 843
 phase II study 342
- phosphorylated tyrosine-containing proteins 1893
 phosphorothioate oligonucleotides 1143
 photochemical 652
 photodynamic therapy 837, 989, 1130, 1343
 piceatannol 774
 pimnidazole 429
 PKB 540, 1586
 placenta weight 89
 plasminogen activator inhibitor type 2 1197
 plasminogen activator inhibitor type-1 1355
 pleiotrophin 858
 Polygenes 76
 polymorphism 568, 1929
 polypoid tumour 1124
 pooled analysis 1085
 poor prognosis 1893
 population mixing 1411
 population studies 76
 population study 1837
 porphobilinogen deaminase 1006
 positron emission tomography (PET) 512, 1052
 postoperative radiotherapy 517
 postoperative survival 1270
 PPAR γ 1303
 predictive factor 1905
 pre-eclampsia 728
 Pre-phase I 1052
 predictive factors 517, 1705
 predictive genetic testing 1209
 pregnancy 1425
 pregnancy choriocarcinoma 26
 primary breast cancer 1217
 probability mapping 870
 prodrug 1348, 1634
 prognosis 185, 222, 402, 417, 568, 1047, 1217, 1578
 prognostic and predictive markers 1457
 prognostic factor 1041
 prognostic factors 674, 686
 prognostic indicators 1797
 prognostic markers 1763
 prognostic value 580
 proliferation 443, 636, 1957, 1963
 proliferation kinetics 517
 prospective cohort study 1081
 prostate 102
 prostate cancer 168, 322, 686, 940, 1136, 1197, 1715
 prostate carcinoma 1465, 1843
 prostate epithelia 1136
 prostate specific antigen 1465
 prostatic neoplasms 70
 proteolysis-inducing factor (PIF) 1628
 proteomics 1440
 protoporphyrin 1006
 PSA 168, 203
 PSA control
 psychological 1540
- psychological distress 43
 psychological impact 233
 PTEN 1586
 pulmonary metastasis 864
 purinergic receptor 636
- quality of life 51, 1243, 1691
 quantitative PCR 1457
 quantitative RT-PCR 580
- R116010 605
 RA 605
 radiation 819, 1929
 radiation response 136
 radiation sensitivity 1143
 radioimmunotherapy 207
 radiolabelled anti-PEM 870
 radiolabelled humanised monoclonal antibody imaging 870
 radionuclide therapy 1715
 radionuclide ventriculography 1697
 radiopharmaceutical 1052
 radiotherapy 470, 686, 744, 1157
 radon 1721
 radon interactions 1727
 raltitrexed 1871
 Ras 1479
 ras oncogene 436
 rat aortic ring assay 796
 rats 1174
 reactive oxygen species 1951
 real-time PCR detection 580
 real-time RT-PCR 899
 receiver operator characteristic curve 899
 receptor 117
 receptor signalling 1250
 rectal cancer 744
 recurrence 1223
 referral patterns 36
 relapse 26
 renal cell carcinoma 185, 1396
 reperfusion injury 989
 replication-selective adenoviruses 5
 repopulation 470
 reproducibility 1741
 reproductive factors 723
 residence 362
 response monitoring 506
 response to treatment 1790
 resuscitation 1057
 resveratrol 774
 RET 1929
 RET/PTC 1929
 RGD-peptides 788
 rhenium-186 HEDT 1715
 ribosomal protein S12 274
 risk factors 70, 712, 723, 1064, 1081, 1373, 1425
 risk management 1209
 risk perceptions 43
 RT-PCR 102, 737, 1322
 ruthenium 993
 ruthenium(II) 1652
- S100A4 409
 salvage regimen 1871
 SCLC 858
 Scotland 1837
 seasonal variation 1070
 secondary lung cancer 1391
 secondary malignancy 239
 segregation analysis 76
 sequential therapy 692
 SEREX 1824
 serine proteases 1457
 serous papillary uterine cancer 151
 service delivery 233
 sexual function 1546
 sexual habits 705
 sialyl Lewis antigens 161
 side effects 1546
 signal transduction pathway 449
 SIR2 917
 skeletal muscle 1012
 small cell lung cancer 558
 smoking 1430, 1757
 smooth muscle 645
 Snail 98
 socio-demographic factors 1034
 SOD-1 779
 solid stress 947
 solid tumours 1566
 sorbitol 1180
 space-time clustering 1070
 spheroid 947
 spheroids 1639
 squamous cell cancer 239
 squamous cell carcinoma 470, 512, 924, 1150
 SR 25989 803
 ST1571 1487
 stage 185
 Stage A chronic lymphocytic leukaemia 31
 staging 1837
 statins 1436
 statistical methods 1093
 ST1571 1333, 1472
 stomach neoplasms 1888
 stromal cells 1639
 structure activity relationships 1652
 subunit composition 285
 suramin 1143
 surgery 1848
 surgical treatment 1223
 surveillance 239
 survival 331, 512, 674, 737, 1790
 survival analysis 1837, 1888
 suspensions 196
 Sweden 732
 SYBR Green I 899
 sympathetic nervous system 117
 symptom control 1540
 symptoms 1373
 synergy 485
 systematic review 501

- TACCI 1824
tamoxifen 218, 402, 761, 1546
tamoxifen therapy 1790
TAP 1943
targeted α therapy 1197
taxotere (docetaxel) 463
Tbdn-I 1824
Tc-99m hHMFG1 870
T-cell functions 168
tegafur 1670
telomerase 917, 1328
temozolomide 501
terminal care 1540
testis 1757
TGF- β 1963
TGF beta 257
theoretical model 14
thienopyridine 803
thiram 779
thrombosis 1813
thymidine phosphorylase 552, 1465
thymidylate synthase 1578
thyroid 917
thyroid cancer 1745
thyroid carcinoma 912
thyroid tumour 1909
thyroid tumours 1929
timing of surgery 1786
T-lymphocytes 409
TNF α 1012, 1396
tobacco 346
tobacco smoke 60
topoisomerase I 1634
topoisomerase inhibitors 1501
toxicity 1634
toxicology 1052
transfection 1586
transformation 257, 1444
translation 1023
translation control 1957
translation initiation factor (eIFs) 1023
treatment by specialist 36
treatment preference 851
treatment response 552
triacylglycerols 963
trophoblastic disease 26
tryptophan 1691
tumour 26, 257, 490, 645, 788
tumour antigens 1824
tumour-associated
 macrophages 1465
tumour blood flow 1604
tumour cells 1310
tumour growth 1803, 1813
tumour hypoxia 429, 619
tumour infiltrating eosinophils 674
tumour lysate 151
tumour markers 506, 1217
tumour metastasis 1597
tumour microcirculation 1622
tumour necrosis factor α 1174
tumour oxygenation 1831
tumour progression 940
tumours 1639
tumour size 396
tumour-specific marker 110
tumour suppression 1923
tumour suppressor 447
tumour suppressor gene 1586
tumour targeting 1322
tumour vascularity 123
tumour vessel 1604
tyrosine kinase 1472
tyrosine kinase inhibitor 456, 1518
ubiquitin-proteasome
 proteolysis 1628
UFT 1670, 1701
ulcerative tumour 1124
uncoupling proteins 372, 612
under-dose 1297
urokinase plasminogen
 activator 1136, 1197, 1355
urothelial cancer 326
utilities 851
vaccination 168
vaccine 336, 1529
vaccines 1336
vascular density 761
vascular endothelial growth
 factor 31, 389, 552, 744
vascular hot spots 301
vascular phenotype 244
vasculature 645
VEGF 301, 417, 558, 858, 864, 1597, 1786
vinflunine 143
viral variant 269
virtual Northern blot 899
vitamin D 680
vitamin K 63
v-Src 463
vulva 924
vulval cancer 756
Waf-1 1117
waiting times 36
WiDr cell line 1162
Wilm's tumour 1920
woman 203
worry 1209
xenograft 470
yeast assay 750
ZD 1839 456, 819, 1157, 1518